GuidelineAnnals of hematology2025
Framework for the comprehensive screening for endocrine disorders in patients with transfusion-dependent thalassemia in low-resource settings.
Guideline in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in managing transfusion-dependent thalassemia (TDT), endocrine complications continue to be a major concern, especially in low-resource settings where delayed diagnosis and inadequate screening lead to higher morbidity. This study aims to develop a practical, evidence-based framework for screening endocrine and metabolic disorders in TDT patients aged 1-16 years in resource-limited environments. Five major guidelines were reviewed, including those from the Thalassemia International Federation (2025), UK Thalassemia Standards (2023), Italian Society for Thalassemia (2022), International Network on Endocrine Complications in Thalassemia (2013), and Oakland Children's Hospital (2012). A multidisciplinary panel of experts analyzed these guidelines along with local data to create a structured screening approach. Local literature highlights significant endocrine challenges, including stunted growth (50.5%, 95% CI: 29.6-71.4) and hypogonadism or delayed puberty (45.8%, 95% CI: -6.5-98.2). Less common issues include hypothyroidism (19.9%), hypoparathyroidism (12.8%), and impaired glucose metabolism (5.0%). A comparative analysis reveals that all guidelines emphasize the importance of clinical evaluation and laboratory testing. However, there are variations in testing panels and screening protocols. The proposed framework highlights clinical assessment as the first step, followed by targeted laboratory testing when resources are limited. Key recommendations include optimizing transfusion and iron chelation to reduce complications, as well as age-specific screening for early detection of endocrinopathies in patients with TDT. This consensus-based approach seeks to standardize endocrine screening for TDT patients, promoting early intervention and referral. Successful implementation will involve training healthcare providers to improve thalassemia care in low-resource settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.